Product specific updates- Shortages

This page contains additional updates on specific medicines currently in short supply.

ADHD medication supply

The supply of a number of ADHD medicines has been affected at various times in 2024 and early 2025. These include medicines containing the following active ingredients:

• guanfacine
• atomoxetine
• lisdexamfetamine dimesylate
• methylphenidate

For some products, while an individual strength may be in short supply, suitable alternatives should be available. In some cases, this may include medicines sourced from other markets via appropriately authorised wholesalers.

We recognise that medicine shortages can be challenging for patients, carers, healthcare professionals and their teams. In January 2024, we  published information to outline the current position and the ongoing coordinated response to minimise impact while supply of these medicines stabilises. See the letter below for more information. 

Supply of medicines used most commonly during winter

At a European level, the HPRA has been working closely with other EU Member States, the European Medicines Agency (EMA), and the European Commission to prepare for the winter season.

The HPRA, the HSE, the Pharmaceutical Society of Ireland (PSI), Medical Council (MCIRL) and the Department of Health are ready to work together with clinical experts and other stakeholders to provide appropriate information and guidance where necessary regarding medicines shortages.

The HPRA is engaging closely with companies and wholesalers involved in the supply of key products. This is to monitor available stock closely and to keep the health system and the public informed. Using information provided by industry, the HPRA will continue monitoring the availability of key medicines throughout this winter period. Should any issues be identified, the potential shortage and mitigating actions will be coordinated through the Medicine Shortages Framework.

The HPRA and health system partners have published information for healthcare professionals and patients to provide reassurance about the availability of key medicines used during the winter season and the efforts taken to monitor the availability on an ongoing basis.

GLP-1 receptor agonist supply

Novo Nordisk, has notified the HPRA of supply issues with its GLP-1 receptor agonist products including Ozempic. This is due to increased global demand for these products and subsequent manufacturing capacity constraints. The company anticipates that intermittent supply issues will continue into 2025.

Novo Nordisk has implemented monthly allocations to help ensure continuity of supply and equitable distribution of stock to Irish patients.

The company has issued letters to relevant stakeholders, including  healthcare professionals, to ensure they are aware of this supply issue and its management. See the August 2024 letter to healthcare professionals below for more information.  

Additional information and HSE guidance relating to this supply interruption is available for healthcare professionals and patients by visiting the Ozempic HCP shortage letter (September 2023) and the GLP1 RA HCP shortage letter (November 2023).

Concerta XL supply

Janssen, the company that places the Concerta XL products on the market, has informed the HPRA that it is encountering global supply chain issues related to component availability and increased demand in multiple markets.

The company has stated that there are allocations in place to ensure equitable distribution to mitigate the impact on patients in Ireland and that it is working closely with pharmacies to ensure patients receive their medication.

The company has advised that if there are any localised supply issues, pharmacies can contact Janssen medical information, on 1800709122, to release the required quantity for the patient.

Janssen has requested that orders are limited to the amount of Concerta XL needed in a given month as the company attempts to build stock levels back up. Ordering more than necessary could increase pressure on the supply levels at a national level.